What knockout strategies are available?

Frameshift mutations, large fragment knockouts, and multiple gene knockouts.

What validation methods do you use?

PCR genotyping, sequencing, and protein expression analysis.

What types of cells can be edited?

We support human, mouse, rat, and other mammalian cell lines.

What is the typical timeline?

KO cell lines can be delivered in as little as 2-3 weeks.

Do you provide functional assays?

Yes, we offer downstream functional analysis and phenotypic validation.

High-Quality Knockout Cell Lines for Reliable Gene Function Studies

Knockout Cell Lines

Understanding gene function is key to biomedical research and drug discovery. Cyagen’s Knockout Cell Line Services deliver precise gene disruption for reliable loss-of-function studies, ensuring high efficiency, complete validation, and fast turnaround to accelerate your research.

Validated & Quality Tested

Genotyping, sequencing, and functional assays confirm accuracy.

Complete KO Assurance

No residual protein expression, ensuring true loss-of-function.

Fast & Reliable Delivery

Standard AAV projects ship in as fast as 2 weeks with rigorous QC testing.

Overview

Workflow

FAQs

Overview

Knockout Cell Lines for Functional Studies

Knockout (KO) cell lines are essential tools for gene function studies, disease modeling, and drug discovery. However, generating reliable KO models can be challenging, with risks of incomplete knockouts, long timelines, and low editing efficiency. Many researchers spend months on KO cell line development, only to face residual protein expression or unsuccessful edits.

Cyagen’s Cell iGeneEditor™ technology overcomes these challenges with high-efficiency gene disruption, rapid turnaround, and customizable deliverables. Our optimized workflow ensures complete target gene knockout, delivering high-quality cell models in as little as 4 weeks.

Explore Ready-to-Use Mouse Models

Discover over 18,000 validated mouse strains—including knockout, conditional knockout, and humanized models—covering 20+ research areas such as oncology, neurology, and metabolism. All models are supported by detailed genotype data and guaranteed quality, helping you fast-track discovery with confidence.

You Might Also Be Interested In

Knockout Cell Lines Library

Browse validated human KO cell lines by gene or cell type

Tumor Cell Lines Library

Access characterized human tumor lines by cancer type or genetic status.

Cell Immunotherapy CRO Platform

CAR-T/NK development with custom vectors, models, and in vivo validation

MouseAtlas Model Library

Search and access curated genetically engineered mouse strains

Targeted Gene Editing

AI-enhanced HDR technology for precise in vivo genome engineering

Knockout Mice

Genetically engineered mice with specific genes fully inactivated for functional studies.

Workflow

Workflow and Delivery

Cyagen provides a streamlined process for knockout cell line development. Below is the typical workflow, estimated turnaround time, and deliverables. For certain specialized cell lines, timelines may vary.

Knockout Cell Line Development & Delivery

Knockout (KO) cell lines provide permanent gene disruption for studying gene function, disease mechanisms, and drug development. Cyagen offers high-efficiency KO cell line generation with rigorous quality control, ensuring reliable loss-of-function models across various cell types.

Deliverables & QC

Cell Type	Example Cell Lines	Deliverables	Quality Control (QC)
Tumor & Immune Cells	Jurkat, HepG2, SK-MES-1	Knokcout clones + matched WT controls (2 vials each, 10⁶ cells/vial) + validation report	PCR, Sanger sequencing, mycoplasma, sterility testing
Non-Cancerous Cells	HK-2, AC16		PCR, Sanger sequencing, mycoplasma, sterility testing

Workflow & Timeline

Stage	Description	Turnaround Time
Cell Expansion & QC	1. Mycoplasma and sterility testing.	1-2 weeks
Guide Molecule & Donor Vector Design	Design and synthesize guide molecules for gene targeting.	1-2 weeks
Electroporation & Clone Selection	1. Electroporate guide molecules into target cells. 2. Screen single clones, extract genomic DNA, and validate knockout through PCR and sequencing.	3-6 weeks
Cryopreservation & Final QC	1. Sequence analysis of the knockout site. 2. Mycoplasma and sterility testing. 3. Viability testing.	1-2 weeks

Note:

Total Estimated Time: 6-12 weeks
Turnaround time may vary based on cell type and project complexity.

iPSC Knockout Cell Line Development & Delivery

iPSC knockout cell lines enable advanced disease modeling and regenerative medicine research. Cyagen’s optimized workflow ensures precise gene knockout in induced pluripotent stem cells while maintaining their pluripotency and differentiation potential.

Deliverables & QC

Cell Type	Example Cell Lines	Deliverables	Quality Control (QC)
iPSC Knockout Cell Lines	H1, H9, iPSC	Differentiated or undifferentiated cell lines	PCR, Sanger sequencing, Immunofluorescence (IF)

Workflow & Timeline

Stage	Description	Turnaround Time
Cell Expansion & QC	1. Mycoplasma and sterility testing. 2. Cell proliferation assessment. 3. Primer design for sequencing the target region.	1-2 weeks
Guide Molecule & Donor Vector Design	Design and synthesize guide molecules for gene targeting.	1-2 weeks
Electroporation & Clone Selection	1. Electroporate guide molecules into target iPSCs. 2. Screen single clones, extract genomic DNA, and validate knockout through PCR and sequencing.	4-6 weeks
Cryopreservation & Final QC	1. Sequence analysis of the knockout site. 2. Mycoplasma and sterility testing. 3. Viability testing. 4. Immunofluorescence staining to verify pluripotency markers.	2 weeks

Note:

Total Estimated Time: 8-12 weeks
Turnaround time may vary for specialized iPSC lines.

FAQs

Citation Database

Molecular Therapy: Methods & Clinical Development, March, 2025

Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing

【Other】

Gut, February, 2025

E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression

【Other】

Cell Death & Disease, February, 2025

Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage

【Other】

Molecular Therapy, February, 2025

Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer

【Other】

Request a Custom Cell Line Consultation

Tell us about your cell line project needs. Our specialists are ready to support your research with tailored solutions.

Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:

Yes, I want to receive updates on products, services, and events from Cyagen.

You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.

By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.